source
- Supernus and Individor to merge, creating $2 billion brain-drug companySupernus and Individor announced a merger that will combine their portfolios of neurological medicines. The two firms together generated about $2 billion in revenue in 2025 from roughly a dozen CN…
- BlossomHill Therapeutics targets $112 million IPO to fund EGFR lung-cancer drug BH-30643BlossomHill Therapeutics, a San Diego oncology biotech, announced plans for an initial public offering to raise about $112 million. The company intends to sell 7.8 million shares at $15-$17 each,…